Role of phosphodiesterases in neurological and psychiatric disease

Current Opinion in Pharmacology

Volumn 7, Issue 1, 2007, Pages 86-92

  Hebb, Andrea LO ^a   Robertson, Harold A ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ALPRAZOLAM; ATROPINE; CLOZAPINE; CYCLIC AMP; CYCLIC GMP; DESIPRAMINE; DIAZEPAM; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; ESTERASE; FLUOXETINE; HALOPERIDOL; HUNTINGTIN; IMIPRAMINE; LEVODOPA; MESSENGER RNA; PAPAVERINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE 10A; PHOSPHODIESTERASE 10A INHIBITOR; PHOSPHODIESTERASE 1B; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE V INHIBITOR; ROLIPRAM; SEROTONIN; SILDENAFIL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANXIETY; ATTENTION DISTURBANCE; BRAIN NERVE CELL; CLINICAL TRIAL; CORPUS STRIATUM; DEPRESSION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TARGETING; ENZYME INHIBITION; ENZYME LOCALIZATION; ERECTILE DYSFUNCTION; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; HUNTINGTON CHOREA; LONG TERM POTENTIATION; MEMORY DISORDER; MENTAL DISEASE; MOOD DISORDER; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SEXUAL AROUSAL DISORDER; SIDE EFFECT; SIGNAL TRANSDUCTION; VOMITING;

ANIMALS; HUMANS; MENTAL DISORDERS; NERVOUS SYSTEM DISEASES; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES;

EID: 33846975147     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2006.08.014     Document Type: Review

References (68)

1. Greengard P. The neurobiology of slow synaptic transmission. Science 294 (2001) 1024-1030
2. Lesch K.P., and Lerer B. The 5-HT receptor-G-protein-effector system complex in depression. I. Effect of glucocorticoids. J Neural Transm Gen Sect 84 (1991) 3-18
3. Majewski H.K., and Musgrave I.F. Second messenger pathways in the modulation of neurotransmitter release. Aust N Z J Med 25 (1995) 817-821
4. Neve K.A., Seamans J.K., and Trantham-Davidson H. Dopamine receptor signaling. J Recept Signal Transduct Res 24 (2004) 165-205
5. Beavo J. Cyclic nucleotide phosphodiesterase: functional implications of multiple isoforms. Physiol Rev 75 (1995) 725-748
6. Conti M., and Jin S.L. The molecular biology of cyclic nucleotide phosphodiesterases. Prog Nucleic Acid Res Mol Biol 63 (1999) 1-38
7. Soderling S.H., and Beavo J.A. Regulation of cAMP and cGMP signaling, new phosphodiesterases and new functions. Curr Opin Cell Biol 12 (2000) 174-179
8. de Vente J., Markerink-van Ittersum M., and Vles J.S. The role of phosphodiesterase isoforms 2, 5 and 9 in the regulation of NO-dependent and NO-independent cGMP production in the rat cervical spinal cord. J Chem Neuroanat 31 (2006) 275-303
9. Seeger T.F., Bartlett B., Coskran T.M., Culp J.S., James L.C., Krull D.L., Lanfear J., Ryan A.M., Schmidt C.J., Strick C.A., et al. Immunohistochemical localization of PDE10A in the rat brain. Brain Res 985 (2003) 113-126
10. Xie Z., Adamowicz W.O., Eldred W.D., Jakowski A.B., Kleiman R.J., Morton D.G., Stephenson D.T., Strick C.A., Williams R.D., and Menniti F.S. Cellular and subcellular localization of PDE10A, a striatum-enriched phosphodiesterase. Neuroscience 139 (2006) 597-607
11. O'Connor V., Genin A., Davis S., Karishma K.K., Doyere V., De Zeeuw C.I., Sanger G., Hunt S.P., Richter-Levin G., Mallet J., et al. Differential amplification of intron-containing transcripts reveals long term potentiation-associated up-regulation of specific PDE10A phosphodiesterase splice variants. J Biol Chem 279 (2004) 15841-15849
12. Perez-Torres S., Miro X., Palacios J.M., Cortes R., Puigdomenech P., and Mengod G. Phosphodiesterase type 4 isozymes expression in human brain examined by in situ hybridization histochemistry and[3H]rolipram binding autoradiography. Comparison with monkey and rat brain. J Chem Neuroanat 20 (2000) 349-374
13. Hebb A.L., Robertson H.A., and Denovan-Wright E.M. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms. Neuroscience 123 (2004) 967-981
14. Zhu J., Mix E., and Winblad B. The antidepressant and anti inflammatory effects of rolipram in the central nervous system. CNS Drug Rev 7 (2001) 387-398
15. Polli J.W., and Kincaid R.L. Expression of a calmodulin-dependent phosphodiesterase isoform (PDE1B1) correlates with brain regions having extensive dopaminergic innervation. J Neurosci 14 (1994) 1251-1261
16. Fujishige K., Kotera J., Michibata H., Yuasa K., Takebayashi S., Okumura K., and Omori K. Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem 274 (1999) 18438-18445
17. Dlaboga D., Hajjhussein H., and O'donnell J.M. Regulation of phosphodiesterase-4 (PDE4) expression in mouse brain by repeated antidepressant treatment: Comparison with rolipram. Brain Res 1096 (2006) 104-112. This paper suggests that the PDE4D subtype might be of particular importance as an antidepressant target. It is regulated by repeated treatment with both norepinephrine and serotonin reuptake inhibitors, as well as by the PDE4 inhibitor rolipram. These drugs produce antidepressant effects via different mechanisms.
18. Fujishige K, Kotera J, Omori K: Striatum- and testis-specific phosphodiesterase PDE10A. Isolation and characterization of a rat PDE10A. Eur J Biochem 1999b, 266:1118-1127.
19. Loughney K., Snyder P.B., Uher L., Rosman G.J., Ferguson K., and Florio V.A. Isolation and characterization of PDE10A, a novel human 3′, 5′-cyclic nucleotide phosphodiesterase. Gene 234 (1999) 109-117
20. Soderling S.H., Bayuga S.J., and Beavo J.A. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc Natl Acad Sci USA 96 (1999) 7071-7076
21. ••] reveal that selective inhibition of PDE10A or genetic deletion of PDE10A has behavioural effects that are consistent with a role in regulation of the activation of striatal medium spiny neurons. The effects of papaverine on conditioned avoidance behaviour are not seen in mice with a null mutation for PDE10A.
22. ••].
23. Hu H., McCaw E.A., Hebb A.L., Gomez G.T., and Denovan-Wright E.M. Mutant huntingtin affects the rate of transcription of striatum-specific isoforms of phosphodiesterase 10A. Eur J Neurosci 20 (2004) 3351-3363
24. Gross-Langenhoff M., Hofbauer K., Weber J., Schultz A., and Schultz J.E. cAMP is a ligand for the tandem GAF domain of human phosphodiesterase 10 and cGMP for the tandem GAF domain of phosphodiesterase 11. J Biol Chem 281 (2006) 2841-2846
25. Tekin S., and Cummings J.L. Frontal-subcortical neuronal circuits and clinical neuropsychiatry: an update. J Psychosom Res 53 (2002) 647-654
26. Gerfen C.R. The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci 15 (1992) 133-139
27. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 109 (2006) 366-398
28. Murphy K.P., Carter R.J., Lione L.A., Mangiarini L., Mahal A., Bates G.P., Dunnett S.B., and Morton A.J. Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. J Neurosci 20 (2000) 5115-5123
29. Furuyama T., Iwashashi Y., Tano Y., Takagi H., and Inahaki S. Localization of 63 kDa calmodulin-stimulated phosphodiesterase mRNA in the rat brain by in situ hybridization histochemistry. Brain Res Mol Brain Res 26 (1994) 331-336
30. Reed T.M., Repaske D.R., Snyder G.L., Greengard P., and Vorhees C.V. Phosphodiesterase 1B knock-out mice exhibit exaggerated locomotor hyperactivity and DARPP-32 phosphorylation in response to dopamine agonists and display impaired spatial learning. J Neurosci 22 (2002) 5188-5197
31. Luthi-Carter R., Strand A., Petters N.L., Solano S.M., Hollingsworth Z.R., Menon A.S., Frey A.S., Spektor B.S., Penney E.B., Schilling G., et al. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum Mol Genet 9 (2000) 1259-1271
32. Challiss R.A., and Nicholson C.D. Effects of selective phosphodiesterase inhibition on cyclic AMP hydrolysis in rat cerebral cortical slices. Br J Pharmacol 99 (1990) 47-52
33. Ye Y., and O'Donnell J.M. Diminished noradrenergic stimulation reduces the activity of rolipram-sensitive, high-affinity cyclic AMP phosphodiesterase (PDE4) in rat brain. J Neurochem 66 (1996) 1894-1902
34. Ye Y., Conti M., Houslay M.D., Farooqui S.M., Chen M., and O'Donnell J.M. Noradrenergic activity differentially regulates the expression of rolipram-sensitive, high-affinity cyclic AMP phosphodiesterase (PDE4) in rat brain. J Neurochem 69 (1997) 2397-2404
35. m, cyclic AMP-specific phosphodiesterase in rat brain. Brain Res Dev Brain Res 112 (1999) 11-19
36. m, cyclic AMP-specific phosphodiesterase in rat brain. Brain Res Dev Brain Res 116 (1999) 181-189
37. Ye Y., Jackson K., and O'Donnell J.M. Effects of repeated antidepressant treatment on Type 4A phosphodiesterase (PDE4A) in rat brain. J Neurochem 74 (2000) 1257-1262
38. van Staveren W.C.G., Markerink-van Ittersum M., Steinbusch H.W.M., and de Vente J. The effects of phosphodiesterase inhibition on cyclic GMP and cyclic AMP accumulation in the hippocampus of the rat. Brain Res 888 (2001) 275-286
39. Giembycz M.A. Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 10 (2001) 1361-1379
40. Jeon Y.H., Heo Y.S., Kim C.M., Hyun Y.L., Lee T.G., Ro S., and Cho J.M. Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development. Cell Mol Life Sci 62 (2005) 1198-1220
41. Duman R.S., Heninger G.R., and Nestler E.J. A molecular and cellular theory of depression. Arch Gen Psychiatry 54 (1997) 597-604
42. Truss M.C., Stief C.G., Uckert S., Becker A.J., Wefer J., Schultheiss D., and Jonas U. Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside. World J Urol 19 (2001) 344-350
43. Sommer N., Loschmann P.A., Northoff G.H., Weller M., Steinbrecher A., Steinbach J.P., Lichtenfels R., Meyermann R., Riethmuller A., and Fontana A. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat Med 1 (1995) 244-248
44. Boolell M., Allen M.J., Ballard S.A., Gepi-Attee S., Muirhead G.J., Naylor A.M., Osterloh I.H., and Gingell C. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 8 (1996) 47-52
45. Moreland R.B., Goldstein I., Kim N.N., and Traish A. Sildenafil citrate, a selective phosphodiesterase 5 inhibitor: research and clinical implications in erectile dysfunction. Trends Endocrinol Metab 10 (1999) 97
46. Bowes C., Li T., Danciger M., Baxter L.C., Applebury M.L., and Farber D.B. Retinal degeneration in the rd mouse is caused by a defect in the B subunit of rod cGMP-phosphodiesterase. Nature 347 (1990) 677-680
47. Hebb AL, Robertson HA, Denovan-Wright EM: Phosphodiesterase 10A inhibition is associated with locomotor and cognitive deficits and increased anxiety in mice. European Neuropsychopharmacology 2007, in press.
48. Hebb A.L.O., Robertson H.A., and Denovan-Wright E. Inhibition of phosphodiesterase 10A activity impairs locomotor and cognitive function in rats. Society for Neuroscience Abstracts 206 (2003) 4
49. ••], this provides support for the idea that PDE10A inhibitors could be useful in psychosis.
50. Sharma T., and Antonova L. Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatr Clin North Am 26 (2003) 25-40
51. Maxwell C.R., Kanes S.J., Abel T., and Siegel S.J. Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications. Neuroscience 129 (2004) 101-107
52. Roberts R.C., Roche J.K., and Conley R.R. Synaptic differences in the postmortem striatum of subjects with schizophrenia: a stereological ultrastructural analysis. Synapse 56 (2005) 185-197
53. Fredholm B.B., Fuxe K., and Agnati L. Effect of some phosphodiesterase inhibitors on central dopamine mechanisms. Eur J Pharmacol 38 (1976) 31-38
54. Craddock N., and Forty L. Genetics of affective (mood) disorders. Eur J Hum Genet 14 (2006) 660-668
55. Porteous D.J., Thomson P., Brandon N.J., and Millar J.K. The genetics and biology of DISC1-an emerging role in psychosis and cognition. Biol Psychiatry 60 (2006) 123-131
56. D'Sa C., Eisch A.J., Bolger G.B., and Duman R.S. Differential expression and regulation of the cAMP-selective phosphodiesterase type 4A splice variants in rat brain by chronic antidepressant administration. Eur J Neurosci 22 (2005) 1463-1475
57. Zhang H.T., Huang Y., Jin S.L., Frith S.A., Suvarna N., Conti M., and O'Donnell J.M. Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme. Neuropsychopharmacology 27 (2002) 587-595
58. Silvestre J.S., Fernandez A.G., and Palacios J.M. Effects of rolipram on the elevated plus-maze test in rats: a preliminary study. J Psychopharmacol 13 (1999) 274-277
59. Cherry J.A., Thompson B.E., and Pho V. Diazepam and rolipram differentially inhibit cyclic AMP-specific phosphodiesterases PDE4A1 and PDE4B3 in the mouse. Biochim Biophys Acta 1518 (2001) 27-35
60. Polesskaya OO, Smith RF, Fryxell KJ: Chronic nicotine doses down-regulate PDE4 isoforms that are target s of antidepressants in adolescent female rats. Biol Psychiatry 2006, in press.
61. Harrison P.J., and Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 10 (2005) 40-68
62. Millar J.K., Pickard B.S., Mackie S., James R., Christie S., Buchanan S.R., Malloy M.P., Chubb J.E., Huston E., Baillie G.S., et al. DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science 310 (2005) 1187-1191. The DISC1 gene is a candidate susceptibility factor for schizophrenia. This paper demonstrates that PDE4B and DISC1 are interacting genetic factors in schizophrenia that regulate cAMP signaling, thus underlining the importance of PDE families in brain function.
63. Sawa A., and Snyder S.H. Genetics. Two genes link two distinct psychoses. Science 310 (2005) 1128-1129
64. Japha K., and Koch M. Picrotoxin in the medial prefrontal cortex impairs sensorimotor gating in rats: reversal by haloperidol. Psychopharmacology (Berl) 144 (1999) 347-354
65. Benes F.M., Burke R.E., Walsh J., Berretta S., Matzilevich D., Minns M., and Konradi C. Acute amygdalar activation induces an upregulation of multiple monoamine G protein. coupled pathways in rat hippocampus. Mol Psychiatry 9 (2004) 932-945 895
66. Zarrindast M.R., Shamsi T., Azarmina P., Rostami P., and Shafaghi B. GABAergic system and imipramine-induced impairment of memory retention in rats. Eur Neuropsychopharmacol 14 (2004) 59-64
67. Rich J.B., Svoboda E., and Brown G.G. Diazepam-induced prospective memory impairment and its relation to retrospective memory, attention, and arousal. Hum Psychopharmacol 21 (2006) 101-108
68. Sharma V. Atypical antipsychotics and suicide in mood and anxiety disorders. Bipolar Disord 5 Suppl 2 (2003) 48-52